Cost of illness in multiple sclerosis by disease characteristics – A review of reviews

References

• Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169–180.
   PubMed Web of Science ®Google Scholar
• Wallin MT, Culpepper WJ, Nichols E, et al. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(3):269–285.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rincon D, Leach B, Pollard J, et al. Exploring the societal burden of multiple sclerosis: a study into the non-clinical impact of the disease, including changes with progression. RAND Corporation: Santa Monica, CA, USA, 2019. [cited 2021 May 31]. Available from: https://www.rand.org/pubs/research_reports/RR4262.html
   Google Scholar
• Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27–40.
   PubMed Web of Science ®Google Scholar
• Kavaliunas A, Danylaite Karrenbauer V, Hillert J. Socioeconomic consequences of multiple sclerosis-A systematic literature review. Acta Neurol Scand. 2021;143(6):587–601.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9(Suppl 1):S5–S48.
   PubMed Web of Science ®Google Scholar
• Wundes A, Brown T, Bienen EJ, et al. Contribution of intangible costs to the economic burden of multiple sclerosis. J Med Econ. 2010;13(4):626–632.
   PubMedGoogle Scholar
• Ziemssen T. Symptom management in patients with multiple sclerosis. J Neurol Sci. 2011;311(Suppl 1):S48–52.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263(6):1053–1065.
   PubMed Web of Science ®Google Scholar
• Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis — success from bench to bedside. Nat Rev Neurol. 2019;15(1):53–58.
   PubMed Web of Science ®Google Scholar
• Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy. 2006;77(1):51–63.
   PubMed Web of Science ®Google Scholar
• Trisolini M, Honeycutt A, Wiener J, et al. Global economic impact of multiple sclerosis. RTI International: Rearch Triangle Park, NC, USA, 2010. [cited 2021 May 31]. Available from: https://www.msif.org/wp-content/uploads/2014/09/Global_economic_impact_of_MS.pdf
   Google Scholar
• Ness NH, Haase R, Kern R, et al. The multiple sclerosis health resource utilization survey (MS-HRS): Development and validation study. J Med Internet Res. 2020;22(3):e17921.
   PubMed Web of Science ®Google Scholar
• Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. PharmacoEconomics. 2011;29(8):653–671.
   PubMed Web of Science ®Google Scholar
• van Lier LI, Bosmans JE, van Hout HPJ, et al. Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study. Eur J Health Econ. 2018;19(7):993–1008.
   PubMed Web of Science ®Google Scholar
• Ernstsson O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis - A systematic review. PloS One. 2016;11(7):e0159129.
   PubMed Web of Science ®Google Scholar
• Stawowczyk E, Malinowski KP, Kawalec P, et al. The indirect costs of multiple sclerosis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):759–786.
   PubMed Web of Science ®Google Scholar
• Oliva-Moreno J, Trapero-Bertran M, Peña-Longobardo LM, et al. The valuation of informal care in cost-of-illness studies: a systematic review. PharmacoEconomics. 2017;35(3):331–345.
   PubMed Web of Science ®Google Scholar
• Diederich F, König HH, Mietzner C, et al. Costs of informal nursing care for patients with neurologic disorders: a systematic review. Neurology. 2018;90(1):28–34.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional observational study in the UK. SSE/EFI Working Paper Series in Economics and Finance; 2000.
   Google Scholar
• Henriksson F, Fredrikson S, Jönsson B. Costs, quality of life and disease severity in multiple sclerosis-A population-based cross-sectional study in Sweden. Stockholm School of Economics; 2000.
   Google Scholar
• Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol. 2001;8(1):27–35.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis: a cross-sectional observational study in Germany. SSE/EFI Working Paper Series in Economics and Finance; 2000.
   Google Scholar
• Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis. An observational study in Germany. The European Journal of Health Economics (HEPAC). 2001;2(2): 60–68.
   Google Scholar
• Kobelt G, Berg J, Atherley D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. SSE/EFI Working Paper Series in Economics and Finance; 2004.
   Google Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696–1702.
   PubMed Web of Science ®Google Scholar
• Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ. 2006;7(Suppl 2):S75–85.
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ. 2006;7(Suppl 2):S55–64.
   PubMedGoogle Scholar
• Kobelt G. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ. 2006;7(Suppl 2):S24–33.
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ. 2006;7(Suppl 2):S45–54.
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ. 2006;7(Suppl 2):S34–44.
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ. 2006;7(Suppl 2):S86–95.
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ. 2006;7(Suppl 2):S14–23.
   PubMedGoogle Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ. 2006;7(Suppl 2):S96–104.
   PubMedGoogle Scholar
• Kobelt G, Texier-Richard B, Lindgren P. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions. Mult Scler. 2009;15(6):741–751.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ. 2006;7(Suppl 2):S65–74.
   PubMedGoogle Scholar
• Battaglia M, Kobelt G, Ponzio M, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy. Mult Scler. 2017;23(2_suppl):104–116.
   PubMed Web of Science ®Google Scholar
• Berger T, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria. Mult Scler. 2017;23(2_suppl):17–28.
   PubMed Web of Science ®Google Scholar
• Boyko A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia. Mult Scler. 2017;23(2_suppl):155–165.
   PubMed Web of Science ®Google Scholar
• Brundin L, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden. Mult Scler. 2017;23(2_suppl):179–191.
   PubMed Web of Science ®Google Scholar
• Calabrese P, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland. Mult Scler. 2017;23(2_suppl):192–203.
   PubMed Web of Science ®Google Scholar
• Dubois B, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium. Mult Scler. 2017;23(2_suppl):29–40.
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany. Mult Scler. 2017;23(2_suppl):78–90.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic. Mult Scler. 2017;23(2_suppl):41–52.
   PubMed Web of Science ®Google Scholar
• Lebrun-Frenay C, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for France. Mult Scler. 2017;23(2_suppl):65–77.
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain. Mult Scler. 2017;23(2_suppl):166–178.
   PubMed Web of Science ®Google Scholar
• Péntek M, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Hungary. Mult Scler. 2017;23(2_suppl):91–103.
   PubMed Web of Science ®Google Scholar
• Rasmussen PV, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark. Mult Scler. 2017;23(2_suppl):53–64.
   PubMed Web of Science ®Google Scholar
• Sá MJ, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal. Mult Scler. 2017;23(2_suppl):143–154.
   PubMed Web of Science ®Google Scholar
• Selmaj K, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland. Mult Scler. 2017;23(2_suppl):130–142.
   PubMed Web of Science ®Google Scholar
• Thompson A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom. Mult Scler. 2017;23(2_suppl):204–216.
   PubMed Web of Science ®Google Scholar
• Uitdehaag B, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands. Mult Scler. 2017;23(2_suppl):117–129.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Teich V, Cavalcanti M, et al. Burden and cost of multiple sclerosis in Brazil. PloS One. 2019;14(1):e0208837.
   PubMed Web of Science ®Google Scholar
• Johansson E, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France. Mult Scler. 2012;18(2 Suppl):17–22.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique. 2012;19(1):e11–25.
   PubMedGoogle Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain. Mult Scler. 2012;18(2 Suppl):35–39.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Germany. Mult Scler. 2012;18(2 Suppl):23–27.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler. 2012;18(2 Suppl):29–34.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, van Munster ET, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ. 2013;16(7):939–950.
   PubMedGoogle Scholar
• Karabudak R, Karampampa K, Calışkan Z. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey. J Med Econ. 2015;18(1):69–75.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom. Mult Scler. 2012;18(2 Suppl):41–45.
   PubMed Web of Science ®Google Scholar
• Hunt H, Pollock A, Campbell P, et al. An introduction to overviews of reviews: planning a relevant research question and objective for an overview. Syst Rev. 2018;7(1):39.
   PubMed Web of Science ®Google Scholar
• Pollock M, Fernandes RM, Becker LA, et al. Chapter V: Overviews of reviews. In: Higgins JPT, Thomas J, Chandler J et al. (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 ( updated February 2021). [cited 2021 May 21]. Available from: http://www.training.cochrane.org/handbook.
   Google Scholar
• Pieper D, Antoine SL, Mathes T, et al. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67(4):368–375.
   PubMed Web of Science ®Google Scholar
• Hennessy EA, Johnson BT. Examining overlap of included studies in meta-reviews: Guidance for using the corrected covered area index. Res Synth Methods. 2020;11(1):134–145.
   PubMed Web of Science ®Google Scholar
• Aromataris E, Fernandez R, Godfrey CM, et al. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015;13(3):132–140.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clin Res Ed). 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Onukwugha E, McRae J, Kravetz A, et al. Cost-of-illness studies: An updated review of current methods. PharmacoEconomics. 2016;34(1):43–58.
   PubMed Web of Science ®Google Scholar
• Jacobs P, Ohinmaa A, Brady B. Providing systematic guidance in pharmacoeconomic guidelines for analysing costs. PharmacoEconomics. 2005;23(2):143–153.
   PubMed Web of Science ®Google Scholar
• Whiting P, Savović J, Higgins JP, Caldwell DM, Reeves BC, Shea B, et al. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225–234.
   PubMed Web of Science ®Google Scholar
• Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.
   PubMed Web of Science ®Google Scholar
• Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Clin Res Ed). 2017;358:j4008.
   PubMed Web of Science ®Google Scholar
• Pieper D, Puljak L, González-Lorenzo M, et al. Minor differences were found between AMSTAR 2 and ROBIS in the assessment of systematic reviews including both randomized and nonrandomized studies. J Clin Epidemiol. 2019;108:26–33.
   PubMed Web of Science ®Google Scholar
• OECD. StatExtracts. PPPs and exchange rates [cited 2021 May 31]. Available from: http://stats.oecd.org/Index.aspx?DataSetCode=SNA_Table4#.
   Google Scholar
• FXTOP. Inflation calculator [ Last accessedcited 2021 May 31]. Available from: https://fxtop.com/en/inflation-calculator.php.
   Google Scholar
• Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11(2):232–239.
   PubMed Web of Science ®Google Scholar
• Grudzinski AN, Hakim Z, Cox ER, et al. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. PharmacoEconomics. 1999;15(3):229–240.
   PubMed Web of Science ®Google Scholar
• Kobelt G. Economic evidence in multiple sclerosis: a review. Eur J Health Econ. 2004;5(Suppl 1):S54–62.
   PubMedGoogle Scholar
• Orlewska E. Economic burden of multiple sclerosis: what can we learn from cost-of-illness studies? Expert Rev Pharmacoecon Outcomes Res. 2006;6(2):145–154.
   PubMedGoogle Scholar
• Naci H, Fleurence R, Birt J, et al. Economic burden of multiple sclerosis: a systematic review of the literature. PharmacoEconomics. 2010;28(5):363–379.
   PubMed Web of Science ®Google Scholar
• Sharac J, McCrone P, Sabes-Figuera R. Pharmacoeconomic considerations in the treatment of multiple sclerosis. Drugs. 2010;70(13):1677–1691.
   PubMed Web of Science ®Google Scholar
• Hu S, Donga P, Zhu G, et al. The burden of multiple sclerosis in China: a literature review. Neurol Asia. 2011;16:3.
   Web of Science ®Google Scholar
• Kolasa K. How much is the cost of multiple sclerosis–systematic literature review. Przeglad Epidemiologiczny. 2013;67(1):75–9, 157–60.
   Google Scholar
• Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639–647.
   PubMedGoogle Scholar
• Romano M, Machnicki G, Rojas JI, et al. There is much to be learnt about the costs of multiple sclerosis in Latin America. Arq Neuropsiquiatr. 2013;71(8):549–555.
   PubMed Web of Science ®Google Scholar
• Fernandez O, Calleja-Hernandez MA, Meca-Lallana J, et al. Estimate of the cost of multiple sclerosis in Spain by literature review. Expert Rev Pharmacoecon Outcomes Res. 2017;17(4):321–333.
   PubMed Web of Science ®Google Scholar
• Paz-Zulueta M, Parás-Bravo P, Cantarero-Prieto D, et al. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020;43:102162.
   PubMed Web of Science ®Google Scholar
• Chataway J, Murphy N, Khurana V, et al. Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities. Curr Med Res Opin. 2021;37(6):995–1004.
   PubMed Web of Science ®Google Scholar
• Dahham J, Rizk R, Kremer I, et al. Economic burden of multiple sclerosis in low- and middle-income countries: A systematic review. PharmacoEconomics. 2021;39(7):789–807.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. EDSS Neurology. 1983;33(11):1444–1452.
   PubMed Web of Science ®Google Scholar
• Inman RP. Disability indices, the economic costs of illness, and social insurance: the case of multiple sclerosis. Acta Neurol Scand Supplementum. 1984;101:46–55.
   PubMedGoogle Scholar
• Bourdette DN, Prochazka AV, Mitchell W, et al. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA multiple sclerosis rehabilitation study group. Arch Phys Med Rehabil. 1993;74(1):26–31.
   PubMed Web of Science ®Google Scholar
• Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. British Journal of Medical Economics. 1995;8:181–193.
   Google Scholar
• Blumhardt L, Wood C. The economics of multiple sclerosis: a cost of illness study. British Journal of Medical Economics. 1996;10:99–118.
   Google Scholar
• Midgard R, Riise T, Nyland H. Impairment, disability, and handicap in multiple sclerosis. A cross-sectional study in an incident cohort in Møre and Romsdal County, Norway. J Neurol. 1996;243(4):337–344.
   PubMed Web of Science ®Google Scholar
• Asche CV, Ho E, Chan B, et al. Economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand. 1997;95(5):268–274.
   PubMed Web of Science ®Google Scholar
• Auty A, Belanger C, Bouchard J, et al. Burden of illness of multiple sclerosis: Part I: cost of illness. Can J Neurosci Nurs. 1998;25(1):23–30.
   Google Scholar
• Henriksson F, Jönsson B. The economic cost of multiple sclerosis in Sweden in 1994. PharmacoEconomics. 1998;13(5 Pt 2):597–606.
   PubMed Web of Science ®Google Scholar
• Murphy N, Confavreux C, Haas J, et al. Economic evaluation of multiple sclerosis in the UK, Germany and France. PharmacoEconomics. 1998;13(5 Pt 2):607–622.
   PubMed Web of Science ®Google Scholar
• Stolp-Smith KA, Atkinson EJ, Campion ME, et al. Health care utilization in multiple sclerosis: a population-based study in Olmsted County, MN. Neurology. 1998;50(6):1594–1600.
   PubMed Web of Science ®Google Scholar
• Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Multiple Sclerosis Journal. 1998;4(5):419–425.
   PubMed Web of Science ®Google Scholar
• Carton H, Loos R, Pacolet J, et al. Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). Journal of Neurology, Neurosurgery & Psychiatry. 1998;64(4):444–450.
   PubMed Web of Science ®Google Scholar
• Carton H, Loos R, Pacolet J, et al. Costs of professional care and informal help of severely disabled multiple sclerosis patients in Flanders (Belgium). Arch Public Health. 1997;55(7–8):239–259.
   Google Scholar
• Carton H, Loos R, Pacolet J, et al. A quantitative study of unpaid caregiving in multiple sclerosis. Multiple Sclerosis Journal. 2000;6(4):274–279.
   PubMed Web of Science ®Google Scholar
• Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Multiple Sclerosis Journal. 2000;6(2):91–98.
   PubMed Web of Science ®Google Scholar
• Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol. 2002;249(2):152–163.
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3(1):17.
   PubMed Web of Science ®Google Scholar
• Russo P, Capone A, Paolillo A, et al. Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Investig. 2004;24(7):409–420.
   PubMed Web of Science ®Google Scholar
• Orlewska E, Mierzejewski P, Zaborski J, et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol. 2005;12(1):31–39.
   PubMed Web of Science ®Google Scholar
• Casado V, Martínez-Yélamos S, Martínez-Yélamos A, et al. Direct and indirect costs of multiple sclerosis in baix llobregat (Catalonia, Spain), according to disability. BMC Health Serv Res. 2006;6(1):143.
   PubMed Web of Science ®Google Scholar
• Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. Journal of Managed Care Pharmacy: JMCP. 2007;13(1):44–52.
   PubMed Web of Science ®Google Scholar
• Taylor B, McDonald E, Fantino B, et al. The cost of multiple sclerosis in Australia. J Clin Neurosci. 2007;14(6):532–539.
   PubMed Web of Science ®Google Scholar
• Tyas D, Kerrigan J, Russell N, et al. The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value Health. 2007;10(5):386–389.
   PubMed Web of Science ®Google Scholar
• Matschay A, Nowakowska E, Hertmanowska H, et al. Cost analysis of therapy for patients with multiple sclerosis (MS) in Poland. Pharmacol Rep. 2008;60(5):632–644.
   PubMed Web of Science ®Google Scholar
• McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK: service use, costs, quality of life and disability. PharmacoEconomics. 2008;26(10):847–860.
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Curr Med Res Opin. 2009;25(4):869–877.
   PubMed Web of Science ®Google Scholar
• Brook RA, Rajagopalan K, Kleinman NL, et al. Absenteeism and health-benefit costs among employees with MS. Curr Med Res Opin. 2009;25(6):1469–1476.
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. PharmacoEconomics. 2009;27(8):681–691.
   PubMed Web of Science ®Google Scholar
• Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. Journal of Managed Care Pharmacy: JMCP. 2010;16(9):703–712.
   PubMed Web of Science ®Google Scholar
• Lad SP, Chapman CH, Vaninetti M, et al. Socioeconomic trends in hospitalization for multiple sclerosis. Neuroepidemiology. 2010;35(2):93–99.
   PubMed Web of Science ®Google Scholar
• Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):205–213.
   PubMed Web of Science ®Google Scholar
• Berto P, Amato M, Bellantonio P, et al. The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. Neurol Sci. 2011;32(6):1035–1041.
   PubMed Web of Science ®Google Scholar
• Curkendall SM, Wang C, Johnson BH, et al. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy. Clin Ther. 2011;33(7):914–925.
   PubMed Web of Science ®Google Scholar
• Gilden DM, Kubisiak J, Zbrozek AS. The economic burden of Medicare-eligible patients by multiple sclerosis type. Value Health. 2011;14(1):61–69.
   PubMed Web of Science ®Google Scholar
• Patti F, Amato MP, Trojano M, et al. Multiple sclerosis in Italy: cost-of-illness study. Neurol Sci. 2011;32(5):787–794.
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Brook RA, Beren IA, et al. Comparing costs and absences for multiple sclerosis among US employees: pre- and post-treatment initiation. Curr Med Res Opin. 2011;27(1):179–188.
   PubMed Web of Science ®Google Scholar
• Reese JP, John A, Wienemann G, et al. Economic burden in a German cohort of patients with multiple sclerosis. Eur Neurol. 2011;66(6):311–321.
   PubMed Web of Science ®Google Scholar
• Blahova Dusankova J, Kalincik T, Dolezal T, et al. Cost of multiple sclerosis in the czech republic: The COMS study. Mult Scler. 2012;18(5):662–668.
   PubMed Web of Science ®Google Scholar
• Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15(3):601–609.
   PubMedGoogle Scholar
• Jennum P, Wanscher B, Frederiksen J, et al. The socioeconomic consequences of multiple sclerosis: a controlled national study. Eur Neuropsychopharmacol. 2012;22(1):36–43.
   PubMed Web of Science ®Google Scholar
• Oleen-Burkey M, Castelli-Haley J, Lage MJ, et al. Burden of a multiple sclerosis relapse: the patient’s perspective. Patient. 2012;5(1):57–69.
   PubMedGoogle Scholar
• Svendsen B, Myhr KM, Nyland H, et al. The cost of multiple sclerosis in Norway. Eur J Health Econ. 2012;13(1):81–91.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Sidovar MF, Roberts MS, et al. Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. PloS One. 2013;8(1):e54756.
   PubMed Web of Science ®Google Scholar
• Macías-Islas MA, Soria-Cedillo IF, Velazquez-Quintana M, et al. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg. 2013;113(4):415–420.
   PubMed Web of Science ®Google Scholar
• Nikfar S, Kebriaeezadeh A, Dinarvand R, et al. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: decision analysis based on long-term clinical data and switchable treatments. Daru. 2013;21(1):50.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Colman S, O’Leary B, et al. The economic impact of multiple sclerosis in Australia in 2010. Mult Scler. 2013;19(12):1640–1646.
   PubMed Web of Science ®Google Scholar
• Parisé H, Laliberté F, Lefebvre P, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci. 2013;330(1–2):71–77.
   PubMed Web of Science ®Google Scholar
• Fogarty E, Walsh C, McGuigan C, et al. Direct and indirect economic consequences of multiple sclerosis in Ireland. Appl Health Econ Health Policy. 2014;12(6):635–645.
   PubMedGoogle Scholar
• Kwiatkowski A, Marissal JP, Pouyfaucon M, et al. Social participation in patients with multiple sclerosis: correlations between disability and economic burden. BMC Neurol. 2014;14:115.
   PubMed Web of Science ®Google Scholar
• Smith W, McCrone P, Goddard C, et al. comparisons of costs between black caribbean and white british patients with advanced multiple sclerosis in the UK. Mult Scler Int. 2014;2014:613701.
   PubMedGoogle Scholar
• Svensson M, Fajutrao L. Costs of formal and informal home care and quality of life for patients with multiple sclerosis in Sweden. Mult Scler Int. 2014;2014:529878.
   PubMedGoogle Scholar
• Svensson J, Borg S, Nilsson P. Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand. 2014;129(1):13–20.
   PubMed Web of Science ®Google Scholar
• Torabipour A, Asl ZA, Majdinasab N, et al. A study on the direct and indirect costs of multiple sclerosis based on expanded disability status scale score in khuzestan, Iran. Int J Prev Med. 2014;5(9):1131–1138.
   PubMedGoogle Scholar
• Ysrraelit C, Caceres F, Villa A, et al. ENCOMS: argentinian survey in cost of illness and unmet needs in multiple sclerosis. Arq Neuropsiquiatr. 2014;72(5):337–343.
   PubMed Web of Science ®Google Scholar
• Zettl UK, Henze T, Essner U, et al. Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). Eur J Health Econ. 2014;15(9):953–966.
   PubMed Web of Science ®Google Scholar
• Ponzio M, Gerzeli S, Brichetto G, et al. Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs. Neurol Sci. 2015;36(2):227–234.
   PubMed Web of Science ®Google Scholar
• Ruutiainen J, Viita AM, Hahl J, et al. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis. J Med Econ. 2016;19(1):21–33.
   PubMed Web of Science ®Google Scholar
• Da Silva NL, Takemoto MLS, Damasceno A, et al. Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study. BMC Health Serv Res. 2016;16:102.
   PubMed Web of Science ®Google Scholar
• Hawton AJ, Green C. Multiple sclerosis: relapses, resource use, and costs. Eur J Health Econ. 2016;17(7):875–884.
   PubMed Web of Science ®Google Scholar
• Buijs S, Krol M, de Voer G. Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database study. J Comp Eff Res. 2018;7(5):453–462.
   PubMed Web of Science ®Google Scholar
• Carney P, O’Boyle D, Larkin A, et al. Societal costs of multiple sclerosis in Ireland. J Med Econ. 2018;21(5):425–437.
   PubMed Web of Science ®Google Scholar
• Gyllensten H, Wiberg M, Alexanderson K, et al. Comparing costs of illness of multiple sclerosis in three different years: a population-based study. Mult Scler. 2018;24(4):520–528.
   PubMed Web of Science ®Google Scholar
• Maia Diniz I, Guerra AAJ, Lovato Pires de Lemos L, et al. The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil. PloS One. 2018;13(6):e0199446.
   PubMed Web of Science ®Google Scholar
• Muñoz-Galindo IM, Moreno Calderón JA, Guarín Téllez NE, et al. Health care cost for multiple sclerosis: The case of a health insurer in Colombia. Value Health Reg Issues. 2018;17:14–20.
   PubMedGoogle Scholar
• Svendsen B, Grytten N, Bø L, et al. The economic impact of multiple sclerosis to the patients and their families in Norway. Eur J Health Econ. 2018;19(9):1243–1257.
   PubMed Web of Science ®Google Scholar
• Bruno D, Marc D, Ouarda P, et al. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. Mult Scler Relat Disord. 2019;36:101396.
   PubMed Web of Science ®Google Scholar
• Chanatittarat C, Prayoonwiwat N, Siritho S, et al. Economic burden of Thai patients with inflammatory demyelinating central nervous system disorders (IDCDs). 2019.
   Google Scholar
• Moccia M, Tajani A, Acampora R, et al. Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: comparison between centre-based and local service healthcare delivery. PloS One. 2019;14(9):e0222012.
   PubMed Web of Science ®Google Scholar
• Blinkenberg M, Kjellberg J, Ibsen R, et al. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: a Danish nationwide population-based study. Mult Scler Relat Disord. 2020;46:102567.
   PubMed Web of Science ®Google Scholar
• Purmonen T, Hakkarainen T, Tervomaa M, et al. Impact of multiple sclerosis phenotypes on burden of disease in Finland. J Med Econ. 2020;23(2):156–165.
   PubMed Web of Science ®Google Scholar
• Ness NH, Schriefer D, Haase R, et al. Differentiating societal costs of disability worsening in multiple sclerosis. J Neurol. 2020;267(4):1035–1042.
   PubMed Web of Science ®Google Scholar
• Ness NH, Schriefer D, Haase R, et al. Real-world evidence on the societal economic relapse costs in patients with multiple sclerosis. PharmacoEconomics. 2020;38(8):883–892.
   PubMed Web of Science ®Google Scholar
• Du Y, Min R, Zhang X, et al. Factors associated with the healthcare expenditures of patients with multiple sclerosis in urban areas of China estimated by a generalized estimating equation. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):137–144.
   PubMed Web of Science ®Google Scholar
• Imani A, Gharibi F, Khezri A, et al. Economic costs incurred by the patients with multiple sclerosis at different levels of the disease: a cross-sectional study in Northwest Iran. BMC Neurol. 2020;20(1):205.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77(8):918–926.
   PubMed Web of Science ®Google Scholar
• Larkin A, O’Rourke K, McGuigan C, et al. Review of the International Literature. In: Societal Cost of Multiple Sclerosis in Ireland 2015. [Last accessed May 31, 2021 ] https://www.ms-society.ie/sites/default/files/2019-06/MS%20Ireland%20-%20Societal%20Cost%20of%20MS%20in%20Ireland%202015cc_0.pdf
   Google Scholar
• Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–1136.
   PubMed Web of Science ®Google Scholar
• Ahmad H, Campbell JA, van der Mei I, et al. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs. Mult Scler Relat Disord. 2020;44:102247.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Chisari CG, Gitto L, et al. Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opin Pharmacother. 2019;20(11):1331–1340.
   PubMed Web of Science ®Google Scholar
• Leggett LE, Khadaroo RG, Holroyd-Leduc J, et al. Measuring resource utilization: A systematic review of validated self-reported questionnaires. Medicine (Baltimore). 2016;95(10):e2759.
   PubMed Web of Science ®Google Scholar
• Bhandari A, Wagner T. Self-reported utilization of health care services: improving measurement and accuracy. Med Care Res Rev MCRR. 2006;63(2):217–235.
   PubMed Web of Science ®Google Scholar
• Stull DE, Leidy NK, Parasuraman B, et al. Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin. 2009;25(4):929–942.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Haase R, Review: ZT. Patient-reported outcomes in multiple sclerosis care. Mult Scler Relat Disord. 2019;33:61–66.
   PubMed Web of Science ®Google Scholar
• Thorn JC, Brookes ST, Ridyard C, et al. Core items for a standardized resource use measure: Expert delphi consensus survey. Value Health. 2018;21(6):640–649.
   PubMed Web of Science ®Google Scholar
• Inojosa H, Schriefer D, Ziemssen T. Clinical outcome measures in multiple sclerosis: a review. Autoimmun Rev. 2020;19(5):102512.
   PubMed Web of Science ®Google Scholar
• Collins CD, Ivry B, Bowen JD, et al. A comparative analysis of patient-reported expanded disability status scale tools. Mult Scler. 2016;22(10):1349–1358.
   PubMed Web of Science ®Google Scholar
• Schriefer D, Haase R, Ettle B, et al. Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study. Eur J Neurol. 2020;27(12):2531–2538.
   PubMed Web of Science ®Google Scholar
• Bamer AM, Cetin K, Amtmann D, et al. Comparing a self report questionnaire with physician assessment for determining multiple sclerosis clinical disease course: a validation study. Mult Scler. 2007;13(8):1033–1037.
   PubMed Web of Science ®Google Scholar
• Tacchino A, Brichetto G, Zaratin P, et al. Self-assessment reliability in multiple sclerosis: the role of socio-demographic, clinical, and quality of life aspects. Neurol Sci. 2019;40(3):617–620.
   PubMed Web of Science ®Google Scholar
• Celius EG, Thompson H, Pontaga M, et al. Disease progression in multiple sclerosis: A literature review exploring patient perspectives. Patient Prefer Adherence. 2021;15:15–27.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Eriksson J, Phillips G, et al. The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms. Mult Scler. 2017;23(2_suppl):4–16.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in Europe: Method of assessment and analysis. Eur J Health Econ. 2006;7(Suppl 2):S5–13.
   PubMedGoogle Scholar
• Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014;95(5):986–95.e1.
   PubMed Web of Science ®Google Scholar
• Amato MP. Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents. Expert Opin Pharmacother. 2004;5(10):2115–2126.
   PubMed Web of Science ®Google Scholar
• Ridyard CH, Hughes DA. Development of a database of instruments for resource-use measurement: purpose, feasibility, and design. Value Health. 2012;15(5):650–655.
   PubMed Web of Science ®Google Scholar